In melanoma patients receiving nivolumab (240 mg intravenous every 2 weeks or 480 mg intravenous every 4 weeks) combined with cabozantinib (40 mg orally daily), should nivolumab be continued indefinitely or discontinued after two years?

Nivolumab Should Be Discontinued After Two Years in Melanoma Patients Receiving Combination Therapy with Cabozantinib

You are correct—when nivolumab is combined with cabozantinib for advanced renal cell carcinoma (the only FDA-approved indication for this combination), nivolumab must be discontinued after 2 years, not continued indefinitely 1.

Critical Clarification: This Combination Is NOT Approved for Melanoma

The nivolumab plus cabozantinib combination is FDA-approved only for advanced renal cell carcinoma, not for melanoma. The FDA label explicitly states: "Nivolumab 240 mg every 2 weeks (30-minute intravenous infusion) or 480 mg every 4 weeks (30-minute intravenous infusion) until disease progression or unacceptable toxicity for up to 2 years" when combined with cabozantinib 40 mg daily 1.

Duration Rules for Melanoma Treatment

For melanoma specifically, the treatment duration depends on the clinical setting:

Adjuvant Melanoma (Post-Resection)

• Nivolumab monotherapy: 1 year (52 weeks) maximum 2
• Dosing: 240 mg IV every 2 weeks or 480 mg IV every 4 weeks 2

Advanced/Metastatic Melanoma

• Nivolumab monotherapy: Continue until disease progression or unacceptable toxicity (no fixed time limit) 2, 3
• Nivolumab plus ipilimumab combination: Ipilimumab for 4 doses only, then nivolumab monotherapy for up to 2 years total 2, 3

Why the Two-Year Rule Exists for Combination Therapy

The 2-year discontinuation rule for nivolumab in combination regimens (whether with ipilimumab in melanoma or cabozantinib in RCC) is based on:

1. Clinical trial design: CheckMate studies established efficacy and safety with fixed-duration combination therapy 4, 5
2. Toxicity management: Extended combination therapy increases cumulative immune-related adverse events
3. Durable responses: Patients achieving response by 2 years often maintain benefit after discontinuation 5, 6

The key distinction is that nivolumab monotherapy in metastatic melanoma can continue indefinitely until progression, but combination regimens have mandated time limits 2, 3.

Common Pitfall to Avoid

Do not extrapolate the cabozantinib-nivolumab regimen from RCC to melanoma—this combination lacks evidence and FDA approval for melanoma. The research study you may be referencing 7 evaluated this combination in non-clear-cell RCC, not melanoma. Another study 8 examined cabozantinib with pembrolizumab (not nivolumab) in melanoma but was terminated early due to low accrual and evolving standards of care.